Concord Biotech Q2 FY27 Revenue Rises 25% to ₹309 Crore on Broad API Growth; Two US ANDA Nods, Inspira Dermatology Launch
Ahmedabad-based fermentation API maker Concord Biotech grew Q2 FY27 revenue 25% to ₹309.1 crore as API sales rose 30%, while solvent and power costs trimmed gross margin; the company added two US ANDA approvals, launched its Inspira dermatology division and is chasing injectables contracts.
